TY - JOUR T1 - Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2020-001931 VL - 9 IS - 1 SP - e001931 AU - Aljosja Rogiers AU - Ines Pires da Silva AU - Chiara Tentori AU - Carlo Alberto Tondini AU - Joseph M Grimes AU - Megan H Trager AU - Sharon Nahm AU - Leyre Zubiri AU - Michael Manos AU - Peter Bowling AU - Arielle Elkrief AU - Neha Papneja AU - Maria Grazia Vitale AU - April A N Rose AU - Jessica S W Borgers AU - Severine Roy AU - Joanna Mangana AU - Thiago Pimentel Muniz AU - Tim Cooksley AU - Jeremy Lupu AU - Alon Vaisman AU - Samuel D Saibil AU - Marcus O Butler AU - Alexander M Menzies AU - Matteo S Carlino AU - Michael Erdmann AU - Carola Berking AU - Lisa Zimmer AU - Dirk Schadendorf AU - Laura Pala AU - Paola Queirolo AU - Christian Posch AU - Axel Hauschild AU - Reinhard Dummer AU - John Haanen AU - Christian U Blank AU - Caroline Robert AU - Ryan J Sullivan AU - Paolo Antonio Ascierto AU - Wilson H Miller Jr AU - F Stephen Hodi AU - Karijn P M Suijkerbuijk AU - Kerry L Reynolds AU - Osama E Rahma AU - Paul C Lorigan AU - Richard D Carvajal AU - Serigne Lo AU - Mario Mandala AU - Georgina V Long Y1 - 2021/01/01 UR - http://jitc.bmj.com/content/9/1/e001931.abstract N2 - Background Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 illness is unknown. The aim of this study was to investigate whether ICI confers an additional risk for severe COVID-19 in patients with cancer.Methods We analyzed data from 110 patients with laboratory-confirmed SARS-CoV-2 while on treatment with ICI without chemotherapy in 19 hospitals in North America, Europe and Australia. The primary objective was to describe the clinical course and to identify factors associated with hospital and intensive care (ICU) admission and mortality.Findings Thirty-five (32%) patients were admitted to hospital and 18 (16%) died. All patients who died had advanced cancer, and only four were admitted to ICU. COVID-19 was the primary cause of death in 8 (7%) patients. Factors independently associated with an increased risk for hospital admission were ECOG ≥2 (OR 39.25, 95% CI 4.17 to 369.2, p=0.0013), treatment with combination ICI (OR 5.68, 95% CI 1.58 to 20.36, p=0.0273) and presence of COVID-19 symptoms (OR 5.30, 95% CI 1.57 to 17.89, p=0.0073). Seventy-six (73%) patients interrupted ICI due to SARS-CoV-2 infection, 43 (57%) of whom had resumed at data cut-off.Interpretation COVID-19–related mortality in the ICI-treated population does not appear to be higher than previously published mortality rates for patients with cancer. Inpatient mortality of patients with cancer treated with ICI was high in comparison with previously reported rates for hospitalized patients with cancer and was due to COVID-19 in almost half of the cases. We identified factors associated with adverse outcomes in ICI-treated patients with COVID-19.All data relevant to the study are included in the article or uploaded as online supplemental information. ER -